FT011 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
51Scleroderma3

51. Scleroderma


Clinical trials : 523 Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005116-21-PL
(EUCTR)
27/09/202125/06/2021FT011 for SclerodermaA phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, oforal FT011 in participants with diffuse systemic sclerosis - FT011 for scleroderma diffuse systemic sclerosis
MedDRA version: 21.0;Level: LLT;Classification code 10012977;Term: Diffuse systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: FT011 100 mg
Product Code: FT011
INN or Proposed INN: None yet
Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
Product Name: FT011 200 mg
Product Code: FT011
INN or Proposed INN: None yet
Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
Certa Therapeutics Pty LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Spain;Poland;Ukraine;Australia;Russian Federation;Netherlands
2EUCTR2020-005116-21-ES
(EUCTR)
22/07/202122/07/2021FT011 for SclerodermaA phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, oforal FT011 in participants with diffuse systemic sclerosis - FT011 for scleroderma diffuse systemic sclerosis
MedDRA version: 21.0;Level: LLT;Classification code 10012977;Term: Diffuse systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: FT011 100 mg
Product Code: FT011
INN or Proposed INN: None yet
Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
Product Name: FT011 200 mg
Product Code: FT011
INN or Proposed INN: None yet
Other descriptive name: 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
Certa Therapeutics Pty LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Poland;Spain;Ukraine;Australia;Russian Federation;Netherlands
3NCT04647890
(ClinicalTrials.gov)
July 19, 202116/11/2020Effects of FT011 in Systemic SclerosisA Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic SclerosisScleroderma, Systemic;Scleroderma, Diffuse;Sclerosis, SystemicDrug: FT011;Drug: PlaceboCerta TherapeuticsNULLRecruiting18 Years75 YearsAll30Phase 2Australia